Drugs / recombinant fowlpox-CEA(6D)/TRICOM vaccine
recombinant fowlpox-CEA(6D)/TRICOM vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00088933 | Jun 2004 → Nov 2007 | non-small cell lung carcinoma, rectal carcinoma, small cell lung carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-CEA(6D)/TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088933 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00088933 ↗ |
| Modality | Vaccine | “Fowlpox-CEA(6D)-TRICOM vaccine” NCT00088933 ↗ |
| Route | Subcutaneous | “fowlpox-CEA-TRICOM vaccine SC on day 1” NCT00088933 ↗ |